Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Polycystic Ovary Syndrome 2Pituitary Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Diabetes Mellitus, Type 2 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 41Radiotherapy 38Cisplatin 35Oxaliplatin 32Leucovorin 24Paclitaxel 22Irinotecan 20Docetaxel 17Neoadjuvant Therapy 14Carboplatin 13Radiation 12Capecitabine 12Surgical Procedures, Operative 10Cetuximab 8Biopsy 8durvalumab 7Gefitinib 7Chemotherapy, Adjuvant 7tremelimumab 6pembrolizumab 6Nivolumab 6Magnetic Resonance Spectroscopy 6Folfox protocol 6Taxes 5Immunohistochemistry 5Endoscopy 5Gene Expression Profiling 4Epirubicin 4Drug Therapy 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma Of Esophagus × Rosiglitazone × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡